Amaryl M (Metformin/Glimepiride)

Product Overview

Amaryl M is a prescription oral antidiabetic medication formulated by Sanofi India Limited for the management of type 2 diabetes mellitus. Each strip contains 15 film‑coated tablets that combine two proven glucose‑lowering agents, metformin and glimepiride, in a sustained‑release (SR) matrix. The product is marketed in pack sizes of 30, 60, and 90 tablets, offering patients a convenient supply for long‑term therapy. Sanofi, a global leader in diabetes care, manufactures Amaryl M under strict Good Manufacturing Practice (GMP) standards, ensuring consistent potency and purity. The sustained‑release design allows for once‑daily dosing, helping to maintain steady plasma concentrations and reduce the frequency of side‑effects associated with rapid drug fluctuations.

What is Amaryl M

Amaryl M belongs to the class of sulfonylurea‑biguanide combination therapies. Metformin, the biguanide component, decreases hepatic glucose production and improves peripheral insulin sensitivity, while glimepiride, a sulfonylurea, stimulates pancreatic beta‑cells to release insulin. The synergistic effect of these two agents provides greater glycemic control than either drug used alone. Because the formulation is released slowly, it avoids the peak concentrations that can trigger hypoglycemia, making it a preferred option for patients who require stable glucose levels throughout the day. Clinical studies indexed in PubMed have demonstrated that combination therapy leads to a mean reduction in HbA1c of approximately 1.2% compared with monotherapy, underscoring its efficacy in the therapeutic armamentarium for type 2 diabetes.

Uses and Benefits

The primary indication for Amaryl M is the improvement of glycemic control in adults with type 2 diabetes who have not achieved target glucose levels through diet and exercise alone. In addition to lowering fasting and post‑prandial glucose, the medication has been shown to reduce body weight modestly when combined with lifestyle modifications, a benefit that distinguishes it from some older sulfonylureas that can cause weight gain. Patients often report improved energy levels and reduced thirst, reflecting better overall metabolic balance. Real‑world data from Drugs.com indicate that adherence is higher with SR formulations because they require only a single daily tablet, simplifying regimen complexity and supporting long‑term persistence.

How It Works

After oral administration, the SR tablet dissolves gradually in the gastrointestinal tract, releasing metformin and glimepiride over approximately 12 hours. Metformin inhibits hepatic gluconeogenesis via activation of AMP‑activated protein kinase (AMPK), while also enhancing muscle glucose uptake. Glimepiride binds to the Kir6.2 subunit of ATP‑sensitive potassium channels on pancreatic beta‑cells, leading to membrane depolarization and insulin secretion. The concurrent action on hepatic output and peripheral insulin release creates a complementary effect that lowers both basal and prandial glucose concentrations. This dual mechanism is reflected in the FDA’s prescribing information, which cites a synergistic reduction in fasting plasma glucose of up to 25 mg/dL when the combination is used at therapeutic doses. For more detailed pharmacology, see the National Institutes of Health.

Dosage Guidelines

The recommended starting dose of Amaryl M is one tablet daily, taken with the morning meal to minimize gastrointestinal upset. Depending on the patient’s response and renal function, the dose may be titrated upward in increments of one tablet at intervals of at least four weeks, with a maximum daily dose of two tablets (equivalent to 2 mg glimepiride and 500 mg metformin). Physicians typically assess renal clearance (eGFR) before initiating therapy; patients with an eGFR below 45 mL/min/1.73 m² should avoid use or receive a reduced dose. It is essential that patients monitor blood glucose regularly and adjust the dose only under medical supervision, as inappropriate dose escalation can increase the risk of hypoglycemia. Information on dosing recommendations can be found on the U.S. Food and Drug Administration website.

Side Effects

Like all antidiabetic agents, Amaryl M may cause adverse effects. The most commonly reported side effects include mild nausea, abdominal discomfort, and diarrhea, which usually resolve after the first few weeks of therapy. More serious but less frequent events comprise hypoglycemia, especially when the medication is combined with insulin or other insulin secretagogues, and lactic acidosis, a rare but potentially life‑threatening condition associated with metformin accumulation in renal impairment. Patients should be instructed to seek immediate medical attention if they experience persistent vomiting, abdominal pain, or unexplained fatigue, which may signal metabolic acidosis. Skin reactions such as rash or pruritus are also possible but typically mild. Additional safety data are available from Drugs.com.

Warnings and Precautions

Amaryl M is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or a history of hypersensitivity to metformin or glimepiride. It should not be used in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²) or in those with hepatic disease that predisposes to drug accumulation. Caution is advised in elderly patients, who may be more susceptible to hypoglycemia, and in patients with endocrine disorders such as adrenal insufficiency or pituitary dysfunction. Concomitant use of certain medications—including contrast agents for imaging studies, some anti‑inflammatory drugs, and high‑dose corticosteroids—can affect glucose control and may require dose adjustments. Pregnant or breastfeeding women should consult a healthcare professional before initiating therapy, as the safety profile during these periods has not been fully established. More information is provided by MedlinePlus.

Frequently Asked Questions

Question 1: What is the difference between Amaryl M and a single‑ingredient diabetes pill? Answer: Amaryl M combines metformin and glimepiride in a single sustained‑release tablet, offering a dual mechanism of action that can achieve greater HbA1c reduction than either component alone. This combination may also reduce the pill burden and improve adherence.

Question 2: Can I take Amaryl M if I have kidney disease? Answer: Patients with an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m² should avoid Amaryl M or use a reduced dose, because metformin is cleared renally and accumulates in impaired kidney function, increasing the risk of lactic acidosis.

Question 3: How long does it take to see improvement in blood sugar levels? Answer: Most patients experience a measurable decrease in fasting glucose within 1–2 weeks of starting therapy, with maximal effects on HbA1c typically observed after 8–12 weeks of consistent use.

Question 4: Is weight loss common with Amaryl M? Answer: weight loss is generally modest and more likely when the medication is combined with dietary changes and physical activity; it is not the primary therapeutic goal but can be an added benefit.

Question 5: Do I need to adjust my diet while using Amaryl M? Answer: Yes. A balanced diet low in simple sugars and regular physical activity are essential components of diabetes management and help to enhance the efficacy of Amaryl M.

Related Products

• Allegra (Fexofenadine)
• Fexofenadine 30 Mg (Generic)
• Fexofenadine 120 Mg (Generic)
• Fexofenadine 180 Mg (Generic)
• Allegra 120 mg (Fexofenadine)
• Allegra 30mg (Fexofenadine)
• Allegra Nasal Duo Spray (Fluticasone / Azelastine)
• Allegra 180 mg (Fexofenadine)
• Okamet 500 Mg (Metformin)
• Framycetin Sulphate Cream (Generic)
• Teicoplanin 400mg (Generic)
• Soframycin Cream (Framycetin Sulphate)